This Review critically evaluates CD38 biology, Fc-mediated immune-effector mechanisms, immune remodeling, clinical evidence, resistance, safety, laboratory interferences, biomarker evidence, and clinical positioning of anti-CD38 antibodies, with multiple myeloma as the central reference disease.
Li-Ming Yu, Chang-Nian Li, Da-Dong Guo et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.